Floatz logo

Methoxyamine

Lung Large Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Lung Large Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
Cis-Diamminedichloroplatinum Ii
National Cancer Institute (NCI)
Phase 3BBB
Etoposide
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine Ditartrate
AIO-Studien-gGmbH
Phase 3BB
Gefitinib
National Cancer Institute (NCI)
Phase 3BB

View all 31 →

Same molecule, other indications

Methoxyamine is also rated in:

neoplasmActive
B
Indicative · Phase 1/2
59 / 100
View asset →
lung adenocarcinomaActive
B
Indicative · Phase 2
58 / 100
View asset →
adult glioblastomaDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →